AVADIM TECHNOLOGIES, INC.

Preventing Global Infections On A Scale

Previously Thought Unachievable

Executive Summary
Pre-IPO Investment Opportunity

Steve Woody
David Fann
Joe McGuire
Paul Cox

Global Infections: A Current Problem A Future Crisis

10,000,000 additional deaths worldwide annually

Safe Harbor Statement

This Executive Summary has been provided to you for informational purposes and is not an offer to
sell or a solicitation of an offer to buy any securities, and may not be relied upon in connection
with the purchase or sale of any security. This Executive Summary does not constitute and should
not be interpreted as either a recommendation or advice, including legal, tax or accounting
advice. Each recipient must perform its own independent investigation and assessment of the
proposed transaction.
Certain information contained in this Executive Summary constitutes forward-looking statements,
which can be identified by the use of forward-looking terminology such as may, will, should,
expect, anticipate, project, estimate, intend, continue or believe or the negatives
thereof or other variations thereon or other comparable terminology. Because of various risks and
uncertainties, including those described in this Executive Summary, actual events or results or the
actual performance of the investment may differ materially from those reflected or contemplated
in such forward-looking statements. No representation or warranty is made about future
performance of the investment or such forward-looking statements.

Avadim Technologies Inc.

The name Avadim means to serve
Our desire is to serve by preventing unnecessary infections
The Avadim Culture is to serve one another, our customers,
and stakeholders.
Success will allow us to give back a percentage of all sales to
the less fortunate

What is Theraworx?

Patented, Disruptive* Technology

Topical Antimicrobial Formula
Non-Toxic, Total Body Safe
Platform Technology With Multiple Applications
Innovative Technology That Spans Across All Three FDA
Classifications: Cosmetic, Monographed Drug, Medical
Device

Disruptive: An innovation that creates a new market by applying a different set of values
which ultimately (and unexpectedly) takes over an existing market. Source: wikipedia

Issue Global Epidemic of Infectious Diseases

Since 1980, approximately 1-3 new human infectious diseases
have been identified annually
Overuse of antibiotics resulting in superbugs
Currently, 700,000 people die annually from superbug infections
By 2050, superbugs will kill 10,000,000; more than cancer

What Are Our Options?

New Drugs
Few New Antibiotic Drugs Are Slated for Release
Drugs Cant be Approved Fast Enough to Keep up with Emerging Diseases
Proliferation of Drug Consumption Only Exacerbates the Issue

Prevent The Infection

Antibiotic Stewardship
Adherence to Evidence Based Protocols and Proven Technologies

The Theraworx Solution

Government
Agencies

Healthcare
Providers

The Science of Theraworx

Primary Functions of the Stratum Corneum

Natural Acidic Antimicrobial Function
Natural Barrier Function

A Breakthrough Discovery
GRAM (-)
BACTERIA

Evidence Based Clinical Overview

SKIN

NON-TOXIC
WOUNDS

BROAD
SPECTRUM
ACTIVITY
BROAD
SPECTRUM
ACTIVITY

NON-TOXIC
MUCOUS
MEMBRANE

GRAM (+)
BACTERIA

13 Clinical Studies over 7 years

YEAST

FUNGI

Randomized Clinical Trials in Process

Stanford University
St. Judes Childrens Research

VIRUSES

Ebola Studies:
Texas Biomedical Research Institute
CDC Study of Efficacy of Theraworx in Liberia

STRATUM
CORNEUM
MANAGEMENT
PERINEUM

FACE

Clinical Market Applications

Childrens
Care

Launched
Catheter
Care

Long Term
Care

Launch In Process
ICU Bathing

Catheter Care
ICU
Bathing

MRSA
Decolonization

Burn and
Trauma
Care

Urine
Analysis

Chronic
Wound Care

Clinical
Applications

2015 Launch
Urine Analysis Kit
Pediatric ICU Bathing

Long Term Care

2016 Launch
Burn Patient Care
MRSA Decolonization

Theraworx Technology Platform:

Revenue Streams from Multiple Markets
Clinical

Consumer

Government

Sales and Marketing Plan

Clinical:

Increase Direct Sales Force from 6 to 13 reps

Increase number of targeted clinical applications from 1 to 6
Expand clinical evidence associated with new applications
Expand existing channel relationships (McKesson, Medline, MedAssets)
Intensify marketing presence (trade shows, magazine articles, etc.)

International:

Partner with governments of emerging third world countries

Establish international manufacturing facilities
Achieve protocol approvals by CDC and WHO

Government:

Domestic Leverage relationship with leading distributor, ADS, and General Gale Pollock to U.S.
Government to promote Combat One.
International Leverage relationship with the RPT Consulting who has established ties to multiple
international governments

Consumer:

Create and develop brands utilizing the Theraworx Platform

Establish strategic partnerships with current leaders in each Industry segment
Support brand to achieve maximum market penetration

Manufacturing Capabilities

FDA Registered Drug Manufacturing Facility

Can Currently Support Sales of $75M

Proprietary, Automated Equipment

Facilities 42,000 Sq. Ft.

ISO 13485 Certified Medical Device Manufacturer

Manufactured in Asheville, NC

Management 175+ years Experience

Steve Woody, Chairman and Chief Executive Officer
Over 25 years of experience in Medical device industry launching over 30 new products new products by
providing Regulatory support and strategic planning
David Fann, President, Director
Responsible for capital raise and new product development. Over $100M raised in 5 public companies.
Joseph F. McGuire, Chief Financial Officer
Over 25 years experience as a Chief Financial Officer with extensive experience in numerous Wall Street
investment vehicles and both private and publicly-traded companies
Jack Payne, National Channel Director
Over 35 years in healthcare, DeRoyal Industries, American Hospital Supply
Jack Hands, National Sales Manager
Over 20 years experience Medical Sales Management, Johnson & Johnson, American Medical Systems
Ron Harvey RN, MSHSA, National Clinical Director, Technical Sales Support Director
Ron provides technical sales support for Critical Care & Long Care Facilities, 31 years as nurse
Paul Cox, Corporate Secretary, Director
Publicly traded, private, growth and finance expertise.
Jared Buckner, Director of Marketing and Product Development
Over 15 years of healthcare manufacturing, business development, and marketing experience
Gale S. Pollock, CRNA, FACHE, FAAN, Major General (Retired), Army Nurse Corps, Commander, US Army
Medical Command and Acting Surgeon General of the Army in 2007 - Currently Serves on Medical Advisory
Board

Corporate Milestones
Milestones

2007
Avadim LLC Formed
Licensed Theraworx

2008-2012
Clinical Trials

2013-2014
Purchased Theraworx
Launched Sales team
Formed Avadim
Technologies, Inc.
Filed Three Patents
Launched Consumer Brands

2015

Expand Clinical Applications

Grow Innergy Sport
Launch Combat One
Launch New Acne Formulation
Expansion of LTC Business
Expansion of African Sales

Revenue Projections
2014 Sales Revenue

120000000

$400,000
100000000

$350,000
$300,000

80000000

$250,000

Revenue
60000000

$200,000

Gross Profit
Net Income

$150,000

40000000

*Estimated

$100,000
20000000

$50,000
$0

JAN

FEB MAR APR MAY JUN

JUL AUG SEP

*projections based on month to month

purchases not long term contracts

Revenue
Gross Profit
Gross Profit Percentage
Net Income

OCT NOV DEC

2015

2016

2017

2012

2013

2014

2015 2016

2017

.20M

0.24M

1.4M

16.3M

48.0M

96.4M

.06M

0.09M

0.9M

11.3M

33.2M

66.7M

30%

38%

64%

69%

69%

69%

-.41M

-1.13M

-1.3M

2.9M

9.1M

19.9M

Based on a set of estimated assumptions. Results will vary.

Theraworx Technology Platform Sales Potential

Pet

Clinical
$200M

$50M

One Science....

International
$200M

Avadim
$750M
Sports
$100M

Cosmetic
$200M

Multiple Solutions.

2015 Critical Path

Capitalization

Expand Sales Team

File of Additional Patents
Expand Clinical Trials
Manufacturing Upgrades
Manufacturing Acquisition

Infrastructure

Sales

$5M PPM
IPO

Expand Clinical Applications

Grow Innergy Sport
Launch Combat One
Launch New Acne Formulation
Expansion of LTC Business
Expansion of African Sales

Valuation
Valuation based on Enterprise Value times Forward Sales Model- Industry Standard
Harvard-MIT Study 352 M&A Transactions
Valuation

Market Cap

Revenues

$1,600,000,000

$37.50

$12,000,000

$1,400,000,000
$10,000,000
$1,200,000,000
$8,000,000
$1,000,000,000

$19.08

$800,000,000

$6,000,000

$600,000,000
$4,000,000

$9.00

$400,000,000

$6.84
$200,000,000

$2.59

$2,000,000

$4.32

$0

$0
3/31/2015

Revenues*
Market Cap*
Stock Price*

6/30/2015

3/31/2015
$676,000
$103,400,000
$2.59

9/30/2015

6/30/2015
$1,200,000
$172,800,000
$4.32

12/31/2015

9/30/2015
$1,900,000
$273,600,000
$6.84

12/31/2016

12/31/2015
$2,500,000
$360,000,000
$9.00

*Revenues, Market cap, and stock price are projected estimates and are not guaranteed.

12/31/2017

12/31/2016
$5,300,000
$763,200,000
$19.08

12/31/2017
$10,400,000
$1,500,000,000
$37.50

Additional Valuation Consideration

Intellectual Property - Our patents and patent-pending protocols.

One Existing Patent
Two Provisional Patents
Four Pending Patents to be Filed in 2015

An acquisition of the assets of a medical manufacturing and packaging company:

Accretive to earnings adds $1,600,000 in 2015.
Accretive to earnings adds $2,500,000 in 2016.
Accretive to earnings adds $3,600,000 in 2017.
Facilitates Manufacturing Efficiencies
Broadens manufacturing capabilities (medical kits for DOD, healthcare, etc.)

The EBOLA Test Results and Protocols

CDC Evaluation in Liberia
World Health Organization Approval

Growth of Sports Medicine Line- Innergy Sport (i.e. Test from University South Carolina to be issued)
Growth of Acne Product Line
Growth of Personal Protection for the T-Zone - TheraZone

A synergistic buyer who applies the investment standard of measuring our business value. Such buyers are often willing to pay a premium for a business
because they can realize some unique advantages through a business purchase. We have been approached by four multi-billion companies in 2014.

Why Invest in Avadim?

Patented Technology
Clinically Validated
Clinically Accepted
Disruptive Technology
Proven Multi-Market

High
Growth
Model

Proven
Technology

Why
Invest

Global Outreach
Giving Back
Eblen Partnership
World Health Organization
Serving Others

Saving
Lives

Government Mandate
70% Gross Profit Model
Multiple Revenue Streams
Global Expansion
Recurring Revenue Model

Current Investment Opportunity

Seeking $5M Equity Investment

Confidential Private Placement Terms

Terms of Offering:
Current Investment Opportunity
$5,000,000 for 2M Shares of Common Stock
$2.50 per share

Use of Proceeds:
Sales and Marketing ($1.4M)
Working Capital ($1.2M)
Launch of New Products
New Patent Applications
Manufacturing Upgrade

Dual Path Exit Strategy

Avadim Technologies to File IPO 2015 (est.)
Current Estimated NASDAQ IPO Pricing TBD
Potential to sell Individual Business Units or Company (All under

NDA)
$3B Catheter Company
$5B Consumer and Medical Revenue Company
$10B Medical Products
$2B Global Medical Company

Contact Information
Joe McGuire
joe@theraworx.com
904.228.2603

David Fann
david@theraworx.com
904.251.4910

Paul Cox
paulcox@pilotagecc.com
604-689-0037

Avadim Technologies, Inc

81 Thompson Street
Asheville, NC 28803
www.theraworx.com